Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 6, Issue 4, Pages 355-362Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2013.811826
Keywords
dimethyl fumarate; fumaric acid; immunomodulation; immune treatment; multiple sclerosis
Categories
Funding
- Bayer Healthcare
- Biogen Idec
- Merck-Serono
- Novartis
- Teva
Ask authors/readers for more resources
Treatments for multiple sclerosis (MS) are only partially effective and most require a parenteral route of administration and/or may have severe side effects. Dimethyl fumarate is the active compound of BG-12 recently licensed for the treatment of relapsing-remitting MS. The pivotal Phase III trials have demonstrated an approximately 50% reduction of relapse rates compared with placebo paralleled by a reduction in new lesion formation on MRI. A dose of 240 mg two-times a day had an optimal effect. Flushing and gastrointestinal symptoms (diarrhea, abdominal pain, nausea) were common adverse events in the first month(s) of treatment. Severe side effects were not more common than in the placebo group for a treatment period of 2 years. The mode of action is not exactly clear and both immunomodulatory effects and an activation of the transcription factor Nrf2 are suggested. This new oral drug will be a welcome addition to existing MS treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available